NASDAQ:REGN Regeneron Pharmaceuticals (REGN) Stock Price, News & Analysis → Who are Nvidia’s New Silent Partners? (From Weiss Ratings) (Ad) Free REGN Stock Alerts $980.57 -3.23 (-0.33%) (As of 05/23/2024 ET) Add Compare Share Share Today's Range$975.73▼$991.7150-Day Range$883.20▼$993.9552-Week Range$684.80▼$998.33Volume315,729 shsAverage Volume480,189 shsMarket Capitalization$108.05 billionP/E Ratio28.97Dividend YieldN/APrice Target$989.36 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Regeneron Pharmaceuticals alerts: Email Address Regeneron Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.76 Rating ScoreUpside/Downside0.9% Upside$989.36 Price TargetShort InterestHealthy1.42% of Shares Sold ShortDividend StrengthN/ASustainability-2.69Upright™ Environmental ScoreNews Sentiment0.75Based on 23 Articles This WeekInsider TradingSelling Shares$53.65 M Sold Last QuarterProj. Earnings Growth8.78%From $37.34 to $40.62 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.96 out of 5 starsMedical Sector180th out of 916 stocksPharmaceutical Preparations Industry65th out of 413 stocks 2.4 Analyst's Opinion Consensus RatingRegeneron Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.76, and is based on 15 buy ratings, 4 hold ratings, and 1 sell rating.Amount of Analyst CoverageRegeneron Pharmaceuticals has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Regeneron Pharmaceuticals' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.42% of the outstanding shares of Regeneron Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverRegeneron Pharmaceuticals has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Regeneron Pharmaceuticals has recently increased by 12.95%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldRegeneron Pharmaceuticals does not currently pay a dividend.Dividend GrowthRegeneron Pharmaceuticals does not have a long track record of dividend growth. Previous Next 2.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRegeneron Pharmaceuticals has received a 8.96% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Aflibercept", "Casirivimab and imdevimab", and "Alirocumab" products. See details.Environmental SustainabilityThe Environmental Impact score for Regeneron Pharmaceuticals is -2.69. Previous Next 2.6 News and Social Media Coverage News SentimentRegeneron Pharmaceuticals has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 23 news articles for Regeneron Pharmaceuticals this week, compared to 15 articles on an average week.Search InterestOnly 9 people have searched for REGN on MarketBeat in the last 30 days. This is a decrease of -18% compared to the previous 30 days.MarketBeat FollowsOnly 8 people have added Regeneron Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Regeneron Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $53,649,186.00 in company stock.Percentage Held by InsidersOnly 8.83% of the stock of Regeneron Pharmaceuticals is held by insiders.Percentage Held by Institutions83.31% of the stock of Regeneron Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Regeneron Pharmaceuticals' insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Regeneron Pharmaceuticals are expected to grow by 8.78% in the coming year, from $37.34 to $40.62 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Regeneron Pharmaceuticals is 28.97, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 138.93.Price to Earnings Ratio vs. SectorThe P/E ratio of Regeneron Pharmaceuticals is 28.97, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 135.83.Price to Earnings Growth RatioRegeneron Pharmaceuticals has a PEG Ratio of 2.05. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRegeneron Pharmaceuticals has a P/B Ratio of 4.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Regeneron Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. About Regeneron Pharmaceuticals Stock (NASDAQ:REGN)Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.Read More REGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart REGN Stock News HeadlinesMay 18, 2024 | insidertrades.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) CEO Leonard S. Schleifer Sells 22,830 SharesMay 17, 2024 | insidertrades.comLeonard S. Schleifer Sells 25,000 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) StockMay 10, 2024 | marketbeat.comWill the Biotech Sector Shift From Lagger to Leader?The biotech sector and its popular ETF, the iShares Biotechnology ETF NASDAQ: IBB, have lagged the overall market during the year, with its shares slightly red. However, in recent weeks, the sector has enjoyed a significant rally after bouncing off its uptrend support and now consolidating near several major Simple Moving Averages (SMA).May 10, 2024 | marketbeat.comWill the Biotech Sector Shift From Lagger to Leader? (REGN)The biotech sector has experienced a significant rally after bouncing off uptrend support and is now consolidating near major SMAs.May 2, 2024 | insidertrades.comInsider Selling: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Insider Sells 16,848 Shares of StockMay 23 at 5:03 PM | globenewswire.comPromising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCOMay 23 at 12:03 PM | businesswire.comMary Kay Awards Grants to Five Aspiring Young Scientists at Regeneron International Science and Engineering FairMay 23 at 6:15 AM | fool.com3 Stocks That Have Turned $25,000 Into More Than $1 Million in 15 YearsMay 22 at 4:50 PM | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGNMay 22 at 1:26 PM | finance.yahoo.comIs Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Trading At A 48% Discount?May 20 at 2:15 PM | globenewswire.comDupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of MedicineMay 20 at 2:15 PM | globenewswire.comPress Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJMMay 20 at 1:34 PM | investorplace.com7 Biotech Stocks That Could Breathe New Life Into Your PortfolioMay 19, 2024 | americanbankingnews.comLeonard S. Schleifer Sells 22,830 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) StockMay 18, 2024 | msn.comRegeneron wins temporary restraining order preventing Eylea generic launch (update)May 17, 2024 | globenewswire.comMore than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024May 16, 2024 | businesswire.comKirby McInerney LLP is Investigating Potential Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN)May 16, 2024 | fool.comThese 2 No-Brainer Growth Stocks Are Breaking New GroundMay 16, 2024 | fool.comThese 2 No-Brainer Growth Stocks Are Breaking New GroundMay 16, 2024 | americanbankingnews.comRegeneron Pharmaceuticals (NASDAQ:REGN) Upgraded by Evercore ISI to Strong-BuyMay 16, 2024 | americanbankingnews.comRegeneron Pharmaceuticals (NASDAQ:REGN) Earns Outperform Rating from Analysts at Evercore ISIMay 14, 2024 | msn.comEvercore ISI Group Initiates Coverage of Regeneron Pharmaceuticals (REGN) with Outperform RecommendationMay 14, 2024 | seekingalpha.comRegeneron Pharmaceuticals Inc (REGN) RBC Capital Markets Global Healthcare Conference (Transcript)May 14, 2024 | finance.yahoo.comRegeneron Pharmaceuticals, Inc. (REGN)May 13, 2024 | markets.businessinsider.comRegeneron : Dupixent SBLA Accepted For FDA Priority Review For Adolescent Chronic RhinosinusitisSee More Headlines Receive REGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/02/2024Today5/23/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:REGN CUSIP75886F10 CIK872589 Webwww.regeneron.com Phone(914) 847-7000Fax914-347-2113Employees13,450Year Founded1988Price Target and Rating Average Stock Price Target$989.36 High Stock Price Target$1,189.00 Low Stock Price Target$720.00 Potential Upside/Downside-0.1%Consensus RatingModerate Buy Rating Score (0-4)2.76 Research Coverage21 Analysts Profitability EPS (Most Recent Fiscal Year)$33.85 Trailing P/E Ratio29.25 Forward P/E Ratio26.51 P/E Growth2.05Net Income$3.95 billion Net Margins29.45% Pretax Margin30.85% Return on Equity16.83% Return on Assets13.16% Debt Debt-to-Equity Ratio0.10 Current Ratio5.27 Quick Ratio4.51 Sales & Book Value Annual Sales$13.12 billion Price / Sales8.32 Cash Flow$43.10 per share Price / Cash Flow22.97 Book Value$244.96 per share Price / Book4.04Miscellaneous Outstanding Shares110,190,000Free Float100,457,000Market Cap$109.09 billion OptionableOptionable Beta0.17 Social Links 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Leonard S. Schleifer M.D. (Age 71)Ph.D., Co-Founder, President, CEO & Co-Chairman Comp: $8.18MDr. George D. Yancopoulos M.D. (Age 64)Ph.D., Co-Founder, President, Chief Scientific Officer & Co-Chairman Comp: $7.76MDr. Andrew J. Murphy Ph.D. (Age 65)Executive Vice President of Research Comp: $1.68MMr. Daniel P. Van Plew (Age 51)Executive VP and GM of Industrial Operations & Product Supply Comp: $2.01MMr. Christopher R. Fenimore CPA (Age 53)Senior VP of Finance & CFO Ms. Patrice GiloolySenior Vice President of Quality Assurance & OperationsMr. Bob McCowanSenior VP of IT & Chief Information OfficerMr. Ryan CroweSenior Vice President of Investor Relations & Strategic AnalysisMr. Joseph J. LaRosa (Age 65)Executive VP, General Counsel & Secretary Comp: $1.75MMs. Melissa LoznerSenior VP & Chief Compliance OfficerMore ExecutivesKey CompetitorsVertex PharmaceuticalsNASDAQ:VRTXGSKNYSE:GSKSanofiNASDAQ:SNYBristol-Myers SquibbNYSE:BMYZoetisNYSE:ZTSView All CompetitorsInsiders & InstitutionsFirst City Capital Management Inc.Bought 223 shares on 5/22/2024Ownership: 0.000%Swedbank ABBought 134,294 shares on 5/21/2024Ownership: 0.122%Atria Investments IncBought 941 shares on 5/21/2024Ownership: 0.008%Sanibel Captiva Trust Company Inc.Sold 56 shares on 5/21/2024Ownership: 0.005%Leonard S SchleiferSold 22,830 sharesTotal: $22.36 M ($979.23/share)View All Insider TransactionsView All Institutional Transactions REGN Stock Analysis - Frequently Asked Questions Should I buy or sell Regeneron Pharmaceuticals stock right now? 21 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 1 sell rating, 4 hold ratings, 15 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" REGN shares. View REGN analyst ratings or view top-rated stocks. What is Regeneron Pharmaceuticals' stock price target for 2024? 21 brokerages have issued 1 year target prices for Regeneron Pharmaceuticals' shares. Their REGN share price targets range from $720.00 to $1,189.00. On average, they anticipate the company's stock price to reach $989.36 in the next year. This suggests a possible upside of 0.9% from the stock's current price. View analysts price targets for REGN or view top-rated stocks among Wall Street analysts. How have REGN shares performed in 2024? Regeneron Pharmaceuticals' stock was trading at $878.29 at the beginning of the year. Since then, REGN shares have increased by 11.6% and is now trading at $980.57. View the best growth stocks for 2024 here. When is Regeneron Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our REGN earnings forecast. How were Regeneron Pharmaceuticals' earnings last quarter? Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) posted its quarterly earnings results on Thursday, May, 2nd. The biopharmaceutical company reported $7.97 earnings per share for the quarter, missing the consensus estimate of $8.46 by $0.49. The biopharmaceutical company earned $3.15 billion during the quarter, compared to the consensus estimate of $3.19 billion. Regeneron Pharmaceuticals had a net margin of 29.45% and a trailing twelve-month return on equity of 16.83%. What ETFs hold Regeneron Pharmaceuticals' stock? ETFs with the largest weight of Regeneron Pharmaceuticals (NASDAQ:REGN) stock in their portfolio include iShares Biotechnology ETF (IBB), Invesco Nasdaq Biotechnology ETF (IBBQ), VanEck Biotech ETF (BBH), Invesco Pharmaceuticals ETF (PJP), ProShares Ultra Nasdaq Biotechnology (BIB), First Trust US Equity Opportunities ETF (FPX), Tema Oncology ETF (CANC) and Invesco Biotechnology & Genome ETF (PBE). What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO? 423 employees have rated Regeneron Pharmaceuticals Chief Executive Officer Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among the company's employees. What other stocks do shareholders of Regeneron Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and Salesforce (CRM). Who are Regeneron Pharmaceuticals' major shareholders? Regeneron Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (8.14%), Capital World Investors (4.22%), Capital International Investors (2.84%), Price T Rowe Associates Inc. MD (0.82%), Bank of New York Mellon Corp (0.81%) and BNP PARIBAS ASSET MANAGEMENT Holding S.A. (0.37%). Insiders that own company stock include Andrew J Murphy, Arthur F Ryan, Arthur F Ryan, Bonnie L Bassler, Bonnie L Bassler, Christine A Poon, Christopher R Fenimore, George L Sing, George Yancopoulos, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Joseph L Goldstein, Leonard S Schleifer, Marc Tessier-Lavigne, Marion Mccourt, Michael S Brown, N Anthony Coles, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Plew Daniel P Van, Robert E Landry and Robert E Landry. View institutional ownership trends. How do I buy shares of Regeneron Pharmaceuticals? Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Regeneron Pharmaceuticals have any subsidiaries? The following companies are subsidiares of Regeneron Pharmaceuticals: Eastside Campus Holdings LLC, Loop Road Holdings LLC, OSMR Holdings, Old Saw Mill Holdings LLC, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, Regeneron Canada Company, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron GmbH, Regeneron Healthcare Solutions Inc., Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron NL B.V., Regeneron Spain S.L.U., Regeneron UK Limited, and Rockwood Road Holdings LLC.Read More This page (NASDAQ:REGN) was last updated on 5/23/2024 by MarketBeat.com Staff From Our Partners[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaBuy this small stock before coming AI Tidal WaveChaikin Analytics**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! Huge Alerts41 banks launch ‘crypto dollar’Stansberry ResearchThe #1 Crypto for AIWeiss RatingsNew Options need New Trading StrategiesNetpicksWrite this ticker symbol down…StocksToTradeExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regeneron Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.